^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | saruparib (AZD5305) (PARP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1270 - The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models
Published date:
03/10/2021
Excerpt:
Hence, we investigated the anti-tumour effects of AZD5305 in combination with carboplatin or paclitaxel in a BRCA1m TNBC xenograft, SUM149PT, and BRCA WT TNBC PDX model, HBCx-9. In both models, combination of AZD5305 with carboplatin was well tolerated and demonstrated clear benefit compared to each monotherapy treatment.
Secondary therapy:
paclitaxel; carboplatin
